141 related articles for article (PubMed ID: 19095951)
21. E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma.
Choi YJ; Lee A; Kim TJ; Jin HT; Seo YB; Park JS; Lee SJ
J Gynecol Oncol; 2018 May; 29(3):e38. PubMed ID: 29400024
[TBL] [Abstract][Full Text] [Related]
22. The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network.
DiGiuseppe S; Bienkowska-Haba M; Hilbig L; Sapp M
Virology; 2014 Jun; 458-459():93-105. PubMed ID: 24928042
[TBL] [Abstract][Full Text] [Related]
23. L2, the minor capsid protein of papillomavirus.
Wang JW; Roden RB
Virology; 2013 Oct; 445(1-2):175-86. PubMed ID: 23689062
[TBL] [Abstract][Full Text] [Related]
24. The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.
Schneider MA; Scheffer KD; Bund T; Boukhallouk F; Lambert C; Cotarelo C; Pflugfelder GO; Florin L; Spoden GA
J Virol; 2013 Apr; 87(8):4461-74. PubMed ID: 23388722
[TBL] [Abstract][Full Text] [Related]
25. Role of L2 cysteines in papillomavirus infection and neutralization.
Gambhira R; Jagu S; Karanam B; Day PM; Roden R
Virol J; 2009 Oct; 6():176. PubMed ID: 19860897
[TBL] [Abstract][Full Text] [Related]
26. Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames.
Firzlaff JM; Kiviat NB; Beckmann AM; Jenison SA; Galloway DA
Virology; 1988 Jun; 164(2):467-77. PubMed ID: 2835863
[TBL] [Abstract][Full Text] [Related]
27. Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein.
Kieback E; Müller M
Virology; 2006 Feb; 345(1):199-208. PubMed ID: 16257028
[TBL] [Abstract][Full Text] [Related]
28. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
[TBL] [Abstract][Full Text] [Related]
29. Study of infectious virus production from HPV18/16 capsid chimeras.
Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
[TBL] [Abstract][Full Text] [Related]
30. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection.
Yang R; Yutzy WH; Viscidi RP; Roden RB
J Biol Chem; 2003 Apr; 278(14):12546-53. PubMed ID: 12560332
[TBL] [Abstract][Full Text] [Related]
31. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
32. An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions.
Huang MZ; Li HB; Nie XM; Wu XY; Jiang XM
Diagn Cytopathol; 2010 Aug; 38(8):573-8. PubMed ID: 19941368
[TBL] [Abstract][Full Text] [Related]
33. Daxx-beta and Daxx-gamma, two novel splice variants of the transcriptional co-repressor Daxx.
Wethkamp N; Hanenberg H; Funke S; Suschek CV; Wetzel W; Heikaus S; Grinstein E; Ramp U; Engers R; Gabbert HE; Mahotka C
J Biol Chem; 2011 Jun; 286(22):19576-88. PubMed ID: 21482821
[TBL] [Abstract][Full Text] [Related]
34. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
35. Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
Day PM; Thompson CD; Schowalter RM; Lowy DR; Schiller JT
J Virol; 2013 Apr; 87(7):3862-70. PubMed ID: 23345514
[TBL] [Abstract][Full Text] [Related]
36. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
37. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
38. Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2.
Florin L; Becker KA; Lambert C; Nowak T; Sapp C; Strand D; Streeck RE; Sapp M
J Virol; 2006 Jul; 80(13):6691-6. PubMed ID: 16775357
[TBL] [Abstract][Full Text] [Related]
39. Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.
Pan WW; Zhou JJ; Liu XM; Xu Y; Guo LJ; Yu C; Shi QH; Fan HY
J Biol Chem; 2013 May; 288(19):13620-30. PubMed ID: 23539629
[TBL] [Abstract][Full Text] [Related]
40. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.
Song MS; Salmena L; Carracedo A; Egia A; Lo-Coco F; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Oct; 455(7214):813-7. PubMed ID: 18716620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
